RayKnowChina Research Map
Shortlist

Beijing

Beijing Chest Hospital

首都医科大学附属北京胸科医院

Listed for 3 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Beijing Chest Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Lung cancer肺癌80 papers led2 open trials led
  2. Neuroblastoma神经母细胞瘤1 paper led
  3. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Lung cancer

肺癌

Led 80 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
80
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
27
led by another institution
Papers led per year
2021: 121220212022: 151520222023: 171720232024: 141420242025: 20202025

20 hospitals in Beijing for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 29

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06421298

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  2. Recruiting
    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06467617

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chest HospitalBeijing

  3. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  4. Recruiting
    Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07222566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  5. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  6. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  7. Recruiting
    Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06712316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou

  8. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  9. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  10. Recruiting
    Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06809764

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou

  11. Recruiting
    A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06855771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen

  12. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  13. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  14. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  15. Recruiting
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07079475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin

  16. Recruiting
    Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07087223

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin

  17. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  18. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  19. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  20. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  21. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  22. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

  23. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  24. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  25. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  26. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  27. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  28. Not yet recruiting
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06885840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  29. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicineRadiation oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led80
  1. Superior Performance of Synchronized Percutaneous Microwave Ablation and Immediate Percutaneous Biopsy for Highly Suspected Malignant Pulmonary Ground-Glass Nodules.2026Journal of computer assisted tomography
  2. Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.2026Lung cancer (Amsterdam, Netherlands)
  3. Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma.2025BMC cancerFree full text
  4. Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.2025BMC cancerFree full text
  5. Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.2025Cancer control : journal of the Moffitt Cancer CenterFree full text
  6. Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.2025Cancer immunology, immunotherapy : CIIFree full text
  7. Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers.2025Cancer medicineFree full text
  8. Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.2025Cancer scienceFree full text
  9. Effect of neoadjuvant targeted therapy on the tumor microenvironment in resectable lung adenocarcinoma.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  10. Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  11. Impact of air pollution on the progress-free survival of non-small cell lung cancer patients with anti-PD-1/PD-L1 immunotherapy: A cohort study.2025Environmental pollution (Barking, Essex : 1987)
  12. Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.2025International immunopharmacology
  13. Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma.2025Journal of clinical pathology
  14. Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.2025Journal of translational medicineFree full text
  15. Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.2025Molecular biomedicineFree full text
  16. CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients.2025Signal transduction and targeted therapyFree full text
  17. A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.2025The oncologistFree full text
  18. Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non-Small Cell Lung Cancer.2025Thoracic cancerFree full text
  19. Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.2025Thoracic cancerFree full text
  20. Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.2025Thoracic cancerFree full text
  21. SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes.2025VirusesFree full text
  22. The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.2025World journal of surgical oncologyFree full text
  23. The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy.2024Advanced biology
  24. Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing.2024AgingFree full text
  25. Artificial intelligence-driven computer aided diagnosis system provides similar diagnosis value compared with doctors' evaluation in lung cancer screening.2024BMC medical imagingFree full text
  26. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers.2024BMC medicineFree full text
  27. Value of preoperative evaluation of FEV1 in patients with destroyed lung undergoing pneumonectomy - a 20-year real-world study.2024BMC pulmonary medicineFree full text
  28. A case of squamous cell carcinoma of the lung misdiagnosed as tuberculosis. Is HPV infected by oral sex the causative agent?2024BMC women's healthFree full text
  29. Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors.2024Biomedical and environmental sciences : BES
  30. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.2024Cancer immunology, immunotherapy : CIIFree full text
  31. The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  32. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.2024Cellular signalling
  33. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.2024European radiology experimentalFree full text
  34. A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.2024Journal of cardiothoracic surgeryFree full text
  35. The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.2024PeerJFree full text
  36. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Associated With Recurrence and Survival of Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Study.2024The Journal of surgical research
  37. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.2023Academic radiology
  38. Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.2023BMC cancerFree full text
  39. Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.2023BMC cancerFree full text
  40. Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.2023BMC pulmonary medicineFree full text
  41. Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study.2023BMC pulmonary medicineFree full text
  42. High accuracy epidermal growth factor receptor mutation prediction via histopathological deep learning.2023BMC pulmonary medicineFree full text
  43. Deep learning-based diagnosis of histopathological patterns for invasive non-mucinous lung adenocarcinoma using semantic segmentation.2023BMJ openFree full text
  44. Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study.2023Cancer letters
  45. Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.2023Cancer medicineFree full text
  46. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.2023European radiology experimentalFree full text
  47. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.2023Frontiers in immunologyFree full text
  48. Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network.2023Frontiers in immunologyFree full text
  49. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.2023Frontiers in immunologyFree full text
  50. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex.2023International journal of biological sciencesFree full text
  51. Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.2023Journal of cancer research and clinical oncologyFree full text
  52. The artificial intelligence and machine learning in lung cancer immunotherapy.2023Journal of hematology & oncologyFree full text
  53. Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.2023Thoracic cancerFree full text
  54. ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.2022Annals of surgical oncology
  55. A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients.2022Annals of surgical oncology
  56. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.2022BMC cancerFree full text
  57. Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis.2022BMC pulmonary medicineFree full text
  58. Expression and potential role of CCL4 in CD8+T cells in NSCLC.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  59. Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  60. CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.2022Clinical and experimental immunology
  61. IncRNA Linc00511 Upregulation Elevates TGFBR1 and Participates in the Postoperative Distant Recurrence of Non-Small-Cell Lung Cancer by Targeting miR-98-5p.2022Critical reviews in eukaryotic gene expression
  62. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.2022Diagnostic pathologyFree full text
  63. Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.2022European journal of radiology
  64. CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.2022Frontiers in immunologyFree full text
  65. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer.2022Immunotherapy
  66. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.2022Lung cancer (Amsterdam, Netherlands)
  67. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.2022Nature communicationsFree full text
  68. Long non-coding RNA BZRAP1-AS1 functions in malignancy and prognosis for non-small-cell lung cancer.2022PeerJFree full text
  69. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.2021Biochemical and biophysical research communications
  70. Identification of a competing endogenous RNA axis "SVIL-AS1/miR-103a/ICE1" associated with chemoresistance in lung adenocarcinoma by comprehensive bioinformatics analysis.2021Cancer medicineFree full text
  71. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.2021Cancer medicineFree full text
  72. Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.2021Drug deliveryFree full text
  73. Associated factors of co-existent pulmonary tuberculosis and lung cancer: A case-control study.2021European journal of clinical investigation
  74. Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.2021Frontiers in endocrinologyFree full text
  75. Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape.2021Molecular cancerFree full text
  76. Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC.2021Molecular oncologyFree full text
  77. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.2021Neoplasma
  78. Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.2021Oncology reportsFree full text
  79. A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer.2021Technology in cancer research & treatmentFree full text
  80. ALK-rearranged squamous cell carcinoma of the lung.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)18
  1. [Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Clinicopathological Characteristics and Prognosis Analysis of 
39 Patients with Pulmonary Sarcomatoid Carcinoma].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment].2024Zhonghua yi xue za zhi
  4. [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. [Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  6. [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  7. [Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  8. [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  9. [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  10. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  11. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  12. [Research Progress of Single Cell Sequencing in Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  13. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  14. [Application Progress of Immune Checkpoint Inhibitors 
in Oncogene-driven Advanced Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  15. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  16. [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  17. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  18. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status96
  1. Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLCRecruitingNCT06467617Lead sponsorPhase 2Start 2024-08
  2. The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03811054Lead sponsorPhase 2Start 2018-12
  3. Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT01669707Lead sponsorPhase 2Start 2011-04
  4. A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.RecruitingNCT06421298Lead (inferred)Phase 2Start 2024-05
  5. A Study of DS-3939a in Participants With Solid TumorsRecruitingNCT07739966Study sitePhase 1/Phase 2Start 2026-10
  6. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingNCT07472517Study sitePhase 3Start 2026-04
  7. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Study sitePhase 3Start 2026-01
  8. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingNCT07195695Study sitePhase 3Start 2026-01
  9. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  10. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Study sitePhase 2Start 2025-03
  11. Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI FailureRecruitingNCT07087223Study sitePhase 1/Phase 2Start 2025-04
  12. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Study sitePhase 3Start 2025-04
  13. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Study sitePhase 3Start 2025-07
  14. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  15. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  16. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingNCT06712355Study sitePhase 3Start 2025-02
  17. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingNCT07079475Study sitePhase 1/Phase 2Start 2025-07
  18. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingNCT06712316Study sitePhase 2/Phase 3Start 2025-01
  19. A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)RecruitingNCT06855771Study sitePhase 2Start 2025-09
  20. Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingNCT06809764Study siteStart 2025-02
  21. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Study sitePhase 3Start 2025-06
  22. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Study sitePhase 3Start 2024-05
  23. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  24. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  25. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Study sitePhase 3Start 2023-11
  26. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Study sitePhase 2Start 2023-12
  27. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  28. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Study sitePhase 2Start 2023-06
  29. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  30. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingNCT05288205Study sitePhase 1/Phase 2Start 2022-04
  31. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Study sitePhase 2Start 2022-09
  32. A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Study sitePhase 1Start 2025-09
  33. A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06623136Study sitePhase 2Start 2025-04
  34. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Study sitePhase 2Start 2025-07
  35. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT07005336Study sitePhase 2Start 2025-01
  36. A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT06469879Study sitePhase 3Start 2024-09
  37. A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingNCT06012435Study sitePhase 3Start 2024-02
  38. A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruitingNCT06593522Study sitePhase 2Start 2024-12
  39. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingNCT06984588Study sitePhase 2/Phase 3Start 2024-03
  40. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Study sitePhase 3Start 2023-10
  41. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryCompletedNCT05872763Study siteStart 2023-08
  42. TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Status unknownNCT05718167Study sitePhase 3Start 2023-02
  43. A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Study sitePhase 3Start 2023-02
  44. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Study sitePhase 3Start 2023-02
  45. Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Study sitePhase 3Start 2023-05
  46. A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.Status unknownNCT05598268Study sitePhase 1/Phase 2Start 2022-03
  47. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  48. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerStatus unknownNCT05042375Study sitePhase 3Start 2022-09
  49. A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05047250Study sitePhase 3Start 2022-06
  50. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Study sitePhase 2Start 2022-06
  51. A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Study sitePhase 3Start 2021-08
  52. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  53. Lorlatinib Continuation StudyActive, not recruitingNCT05144997Study sitePhase 4Start 2021-12
  54. Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Study sitePhase 3Start 2021-04
  55. A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerCompletedNCT04426825Study sitePhase 2Start 2020-09
  56. Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04665856Study sitePhase 3Start 2020-12
  57. A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04513925Study sitePhase 3Start 2020-08
  58. Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Study sitePhase 3Start 2020-10
  59. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Study siteStart 2020-07
  60. Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Study sitePhase 3Start 2020-10
  61. TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsCompletedNCT04129502Study sitePhase 3Start 2020-01
  62. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Study sitePhase 3Start 2020-04
  63. Cancer Genome Atlas of China:Lung CancerStatus unknownNCT04266483Study siteStart 2019-11
  64. ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCStatus unknownNCT04143607Study sitePhase 3Start 2019-07
  65. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Study sitePhase 3Start 2019-08
  66. A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Study sitePhase 2Start 2019-04
  67. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedNCT03596866Study sitePhase 3Start 2019-04
  68. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  69. Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedNCT04044170Study sitePhase 2Start 2019-07
  70. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  71. The Tracking Molecular Evolution for NSCLC (T-MENC) StudyStatus unknownNCT03838588Study siteStart 2018-11
  72. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Study sitePhase 3Start 2018-08
  73. Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung CancerCompletedNCT03432598Study sitePhase 2Start 2017-08
  74. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Study sitePhase 3Start 2017-11
  75. Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownNCT03502850Study sitePhase 1/Phase 2Start 2017-11
  76. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Study sitePhase 3Start 2016-07
  77. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  78. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Study sitePhase 3Start 2016-06
  79. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Study sitePhase 3Start 2016-08
  80. A Study of TAK-788 in Adults With Non-Small Cell Lung CancerCompletedNCT02716116Study sitePhase 1/Phase 2Start 2016-06
  81. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)CompletedNCT02388919Study sitePhase 2/Phase 3Start 2015-02
  82. A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02691299Study sitePhase 3Start 2015-12
  83. Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung CancerStatus unknownNCT02933294Study siteN/AStart 2015-05
  84. High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Study sitePhase 4Start 2015-04
  85. Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaStatus unknownNCT02125240Study sitePhase 3Start 2014-09
  86. A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02590965Study sitePhase 2Start 2014-05
  87. Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCCompletedNCT01945021Study sitePhase 2Start 2013-09
  88. Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)CompletedNCT01982955Study sitePhase 1/Phase 2Start 2013-12
  89. Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung CancerCompletedNCT01836679Study sitePhase 2Start 2013-04
  90. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Study sitePhase 3Start 2012-09
  91. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyCompletedNCT01364012Study sitePhase 3Start 2011-05
  92. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung CancerCompletedNCT03117335Study sitePhase 3Start 2011-11
  93. Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Study sitePhase 3Start 2010-03
  94. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)CompletedNCT01121393Study sitePhase 3Start 2010-04
  95. Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Study sitePhase 3Start 2009-02
  96. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian PopulationTerminatedNCT01015443Study sitePhase 3Start 2009-12

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

23 hospitals in Beijing for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Protective effect of anti-idiopathic pulmonary fibrosis drug Pirfenidone and Sufenidone (SC1011) on pulmonary injury induced by tuberculosis in a mouse tuberculosis model].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary FibrosisNot yet recruitingNCT07515066Lead (inferred)Phase 1Start 2026-05

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京胸科医院

Beijing Chest Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Beijing Thoracic Tumor and Tuberculosis Hospital; Central Tuberculosis Institute

Suggest a correctionDownload the data